[Application of 2% clindamycin cream in the treatment of bacterial vaginosis and valuation of methylcellulose gel containing the complex of Chitosan F and PVP k-90 with lactic acid as carrier for intravaginally adhbited medicines in the cases of pregnancies with the symptoms of preterm delivery].
OBJECTIVE
There are many reports informing about the connection between BV and the increased risk of preterm delivery. The reason of self-concession and reversion of BV after having executed an efficient treatment has not yet been properly explained.


METHODS
The aim of this work was the clinical valuation of the 2% Clindamycin cream in the treatment of BV and of the methylcellulose gel containing the complex of Chitosan F and PVP K-90 with lactic acid as a carrier for intravaginally adhbited medicines in the cases of pregnancies with the symptoms of a preterm delivery.


METHODS
The research comprised 145 pregnant between 24-34 week of pregnancy, hospitalised because of the symptoms of a preterm menace delivery. In the case of the detection of BV, a 10-day therapy using intravaginal cream containing 2% Clindamycin was executed. In the cases not qualified as BV, the methylcellulose gel containing the complex of Chitosan F and PVP K-90 with lactic acid has been intravaginally adhibited for 10 days.


CONCLUSIONS
1. Application of 2% Clindamycin cream is an efficient method of the treatment of bacterial vaginosis. 2. Methylcellulose gel containing lactic acid combined with the complex of Chitosan F and PVP K-90 allows a persistent maintenance of the correct pH of vagina. 3. Methylcellulose gel, because of its physico-chemical properties similar to physiological mucus, is a universal carrier for intravaginally adhibited medicines.
Hirnle
L
L
Katedry i Kliniki Rozrodczości AM we Wrocławiu.
Heimrath
J
J
Woytoń
J
J
Kłósek
A
A
Hirnle
G
G
Małolepsza-Jarmołowska
K
K
D000282:Administration, Intravaginal; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002686:Chitin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D048271:Chitosan; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005782:Gels / Q000627:therapeutic use; D006801:Humans; D019344:Lactic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D008747:Methylcellulose / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000209:etiology*; D009824:Ointments / Q000627:therapeutic use; D010592:Pharmaceutic Aids / Q000627:therapeutic use; D011205:Povidone / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D016896:Treatment Outcome; D016585:Vaginosis, Bacterial / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D005782:Gels; D009824:Ointments; D010592:Pharmaceutic Aids; D002686:Chitin; D019344:Lactic Acid; D002981:Clindamycin; D008747:Methylcellulose; D048271:Chitosan; D011205:Povidone